Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (697)	5/3/1998 10:18:00 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 1491

The HU211 trial has just started enrolling the third, highest dose cohort, Pharmos having just received permission to escalate the dose from the Israeli authorities. The most interesting question is whether they will unblind the first two cohorts to establish the true magnitude of effect (we have all been reading between the lines of the 12.5% overall mortality rate)....or wait for the third cohort to complete (end98, early 99)in order to maximize statistical power. My suggestion has been to unblind; this is not a pivotal trial where one must maximize power to pass FDA scrutiny...they simply need to show enough effect (and safety) to convince Big Pharma partners to place their bids. NeuroInvestment (www.neuroinv.com)

To: David Israel-Rosen who wrote (697)	5/4/1998 8:45:00 PM
From: arnie h	Read Replies (1) \| Respond to of 1491

Ah David: Thanks for your assurances we won't keep getting diluted. I hope you're right. Still wondering though because I remember reading the agreement as being in 2 parts; the first for $5M and the second for $3M, at a later time. I haven't rechecked the details so my memory may be faulty. At any rate, time will tell. Also wondering why Elliot et al. are now gone. Have they disposed of all their stock and warrants? Thanks also for your comments on trial location. One very attractive aspect of PARS is its leverage. Seem to get a lot done with limited funds. Regards, Arnie